Search

Your search keyword '"Barroso, Fabio"' showing total 222 results

Search Constraints

Start Over You searched for: Author "Barroso, Fabio" Remove constraint Author: "Barroso, Fabio"
222 results on '"Barroso, Fabio"'

Search Results

1. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen

2. Utilidad de la identificación de anticuerpos en miopatías inflamatorias: revisión

3. Utilidad de los anticuerpos en las enfermedades de la unión neuromuscular: revisión

5. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey

7. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

10. Utilidad de la identificación de anticuerpos en neuropatías periféricas, neuronopatías y ganglionopatías: revisión

11. Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score

13. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

14. Guillain–Barré Syndrome and COVID-19 Vaccine: A Multicenter Retrospective Study of 46 Cases

16. Estudio epidemiológico multicéntrico sobre esclerosis lateral amiotrófica en la Ciudad de Buenos Aires

17. Cerebrospinal Fluid Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome

18. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.

19. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen

24. Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS)

25. Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values.

26. Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS) : 14-year update

27. An International Perspective on Preceding Infections in Guillain-Barre Syndrome The IGOS-1000 Cohort

28. Predicting Outcome in Guillain-Barre Syndrome International Validation of the Modified Erasmus GBS Outcome Score

29. Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values

30. Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study:Differences in methods and reference values

31. Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score

32. Neuralgic amyotrophy detected by magnetic resonance neurography: subclinical, bilateral, and multifocal brachial plexus involvement.

33. Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS)

35. Utilidad de los anticuerpos en las enfermedades de la unión neuromuscular: revisión

36. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey

37. Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study

38. Intravenous immunoglobulin treatment for mild Guillain-Barre syndrome: an international observational study

39. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab:subgroup analysis of REGAIN and its extension study

40. Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome:an international observational study

42. ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

43. Síndrome miasteniforme de Lambert-Eaton

44. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

45. An International Perspective on Preceding Infections in Guillain-Barré Syndrome

48. Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study

49. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

Catalog

Books, media, physical & digital resources